Profiling cMet Pathway Inhibition in Prostate Cancer

TMT®MS2 Broadest Coverage Workflow
TMT®SRM Assay Development

Goal – Discovery and validation of biomarkers to assess the response to cMet inhibition and functional inactivation

Outcome - 170 novel biomarkers identified in discovery, BioTag TMT®SRM assay developed to validate the top 28 markers

Collaborators - ProQinase GmBH, Germany & Natural Medical Sciences Institute, University of Tubingen, Germany

View all case studies